The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Bioline Introduces New SensiFAST™ HRM Kit for Gene Mutations and SNP Analysis

Thursday, February 16, 2012

Bioline Introduces New SensiFAST™ HRM Kit for Gene Mutations and SNP Analysis07:00 EST Thursday, February 16, 2012 CINCINNATI (Business Wire) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition to its SensiFAST family real-time PCR products. SensiFAST HRM Kit facilitates High Resolution Melt (HRM) curve analysis, enabling amplification and discrimination of even the most challenging sequence differences (such as class 4 SNPs) without sequence preference. SensiFAST HRM is designed to deliver fast, accurate detection of gene mutations and SNPs and provides reliable and highly reproducible data on all commonly used real-time PCR instruments, especially the new generation of fast-cyclers. Since SensiFAST HRM does not require expensive labeled oligonucleotide probes, it is a cost-effective alternative to traditional probe based genotyping methods. Marco Calzavara, President of Bioline commented, "I am delighted to announce the release of SensiFAST HRM as a new member of our real-time PCR-based SensiFAST family. This new kit will enable researchers to cost-effectively scan DNA from a variety of biological sample types to detect the smallest genetic variations among samples.” Richard L. Eberly, Chief Commercial Officer of Meridian Bioscience, Inc., stated, “The release of SensiFAST HRM Kit is part of a new generation of products to advance the rapidly expanding portfolio of highly specialized molecular biology reagents from Bioline. We remain committed to our life science customers to bring innovation and quality products to the research lab, clinical diagnostic laboratories, and biotechnology companies.” ABOUT MERIDIAN BIOSCIENCE, INC. Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com. ADDITIONAL INFORMATION For more information about Bioline, please visit www.bioline.comFor more information about Meridian Life Science, Inc., please visit www.meridianlifescience.comFor more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com Meridian Bioscience, Inc.Richard L. Eberly, Chief Commercial Officer, 513-271-3700rick.eberly@meridianbioscience.com